المؤلفون: Corbaux, Pauline, You, Benoit, Glasspool, Rosalind M., Yanaihara, Nozomu, Tinker, Anna V., Lindemann, Kristina, Ray-Coquard, Isabelle Laure, Mirza, Mansoor Raza, Subtil, Fabien, Colomban, Olivier, Péron, Julien, Karamouza, Eleni, Mcneish, Iain A., Kelly, Caroline A., Kagimura, Tatsuo, Welch, Stephen A., Lewsley, Liz Anne, Paoletti, Xavier, Cook, Adrian D.

المساهمون: Centre pour l'innovation en cancérologie de Lyon (CICLY), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre Léon Bérard Lyon, Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut Curie Paris, Groupe d'Investigateurs National des Etudes des Cancers Ovariens et du sein, Gynaecologic Cancer Intergroup, University Claude Bernard, Hospices Civils de Lyon, HCL

المصدر: ISSN: 0959-8049 ; European Journal of Cancer ; https://hal.science/hal-04229567Test ; European Journal of Cancer, 2023, 191, ⟨10.1016/j.ejca.2023.112966⟩.

مصطلحات موضوعية: CA-125, KELIM, Ovarian cancer, Primary chemosensitivity, Prognostic biomarker, Surrogate end-point, [SDV.CAN]Life Sciences [q-bio]/Cancer

الوصف: International audience ; Background: In patients with advanced ovarian cancer, the modelled CA-125 ELIMination rate constant K (KELIM) is an early indicator of the tumour intrinsic chemosensitivity. We assessed the prognostic and surrogate values of KELIM with respect to those of surgery outcome (based on post-operative residual lesions) in the Gynaecologic Cancer Intergroup (GCIG) individual patient data meta-analysis MAOV (Meta-Analysis in OVarian cancer) built before the emergence of poly(ADP-ribose) polymerase (PARP) inhibitors. Methods: The dataset was split into learning and validation cohorts (ratio 1:2). The individual modelled KELIM values were estimated, standardised by the median value, then scored as unfavourable (<1.0) or favourable (≥1.0). Overall survival (OS) and progression-free survival (PFS) analyses were performed with a two-step meta-analytic approach and surrogacy through a two-level meta-analytic model. Results: KELIM was assessed in 5884 patients from eight first-line trials (learning, 1962; validation, 3922). A favourable KELIM score was significantly associated with longer OS (validation set, median, 78.8 versus 28.4 months, hazard-ratios [HR] 0.46, 95% confidence interval [CI], 0.41–0.50, C-index 0.68), and longer PFS (validation set, median 30.5 versus 9.8 months, HR 0.49, 95% CI, 0.45–0.54, C-index 0.68), as were International Federation of Gynaecology and Obstetrics (FIGO) stage and debulking surgery outcome. Three prognostic groups were identified based on the surgery outcome and KELIM score, with large differences in OS (105.1, ∼45.0, and 22.1 months) and PFS (58.1, ∼15.0, and 8.0 months). Surrogacy for OS and for PFS was not established. Conclusion: KELIM is an independent prognostic biomarker for survival, complementary to surgery outcome, representing a new determinant of first-line treatment success.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37542936; hal-04229567; https://hal.science/hal-04229567Test; https://hal.science/hal-04229567/documentTest; https://hal.science/hal-04229567/file/1-s2.0-S0959804923003180-main.pdfTest; PUBMED: 37542936

الإتاحة: https://doi.org/10.1016/j.ejca.2023.112966Test
https://hal.science/hal-04229567Test
https://hal.science/hal-04229567/documentTest
https://hal.science/hal-04229567/file/1-s2.0-S0959804923003180-main.pdfTest

المؤلفون: Corbaux, Pauline, You, Benoit, Glasspool, Rosalind M., Yanaihara, Nozomu, Tinker, Anna V., Lindemann, Kristina, Ray-Coquard, Isabelle Laure, Mirza, Mansoor Raza, Subtil, Fabien, Colomban, Olivier, Péron, Julien, Karamouza, Eleni, Mcneish, Iain A., Kelly, Caroline A., Kagimura, Tatsuo, Welch, Stephen A., Lewsley, Liz Anne, Paoletti, Xavier, Cook, Adrian D.

المساهمون: Centre pour l'innovation en cancérologie de Lyon (CICLY), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre Léon Bérard Lyon, Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut Curie Paris, Groupe d'Investigateurs National des Etudes des Cancers Ovariens et du sein, Gynaecologic Cancer Intergroup, University Claude Bernard, Hospices Civils de Lyon, HCL

المصدر: ISSN: 0959-8049 ; European Journal of Cancer ; https://hal.science/hal-04229567Test ; European Journal of Cancer, 2023, 191, ⟨10.1016/j.ejca.2023.112966⟩.

مصطلحات موضوعية: CA-125, KELIM, Ovarian cancer, Primary chemosensitivity, Prognostic biomarker, Surrogate end-point, [SDV.CAN]Life Sciences [q-bio]/Cancer

الوصف: International audience ; Background: In patients with advanced ovarian cancer, the modelled CA-125 ELIMination rate constant K (KELIM) is an early indicator of the tumour intrinsic chemosensitivity. We assessed the prognostic and surrogate values of KELIM with respect to those of surgery outcome (based on post-operative residual lesions) in the Gynaecologic Cancer Intergroup (GCIG) individual patient data meta-analysis MAOV (Meta-Analysis in OVarian cancer) built before the emergence of poly(ADP-ribose) polymerase (PARP) inhibitors. Methods: The dataset was split into learning and validation cohorts (ratio 1:2). The individual modelled KELIM values were estimated, standardised by the median value, then scored as unfavourable (<1.0) or favourable (≥1.0). Overall survival (OS) and progression-free survival (PFS) analyses were performed with a two-step meta-analytic approach and surrogacy through a two-level meta-analytic model. Results: KELIM was assessed in 5884 patients from eight first-line trials (learning, 1962; validation, 3922). A favourable KELIM score was significantly associated with longer OS (validation set, median, 78.8 versus 28.4 months, hazard-ratios [HR] 0.46, 95% confidence interval [CI], 0.41–0.50, C-index 0.68), and longer PFS (validation set, median 30.5 versus 9.8 months, HR 0.49, 95% CI, 0.45–0.54, C-index 0.68), as were International Federation of Gynaecology and Obstetrics (FIGO) stage and debulking surgery outcome. Three prognostic groups were identified based on the surgery outcome and KELIM score, with large differences in OS (105.1, ∼45.0, and 22.1 months) and PFS (58.1, ∼15.0, and 8.0 months). Surrogacy for OS and for PFS was not established. Conclusion: KELIM is an independent prognostic biomarker for survival, complementary to surgery outcome, representing a new determinant of first-line treatment success.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37542936; hal-04229567; https://hal.science/hal-04229567Test; https://hal.science/hal-04229567/documentTest; https://hal.science/hal-04229567/file/1-s2.0-S0959804923003180-main.pdfTest; PUBMED: 37542936

الإتاحة: https://doi.org/10.1016/j.ejca.2023.112966Test
https://hal.science/hal-04229567Test
https://hal.science/hal-04229567/documentTest
https://hal.science/hal-04229567/file/1-s2.0-S0959804923003180-main.pdfTest

المؤلفون: Corbaux, Pauline, You, Benoit, Glasspool, Rosalind M., Yanaihara, Nozomu, Tinker, Anna V., Lindemann, Kristina, Ray-Coquard, Isabelle Laure, Mirza, Mansoor Raza, Subtil, Fabien, Colomban, Olivier, Péron, Julien, Karamouza, Eleni, Mcneish, Iain A., Kelly, Caroline A., Kagimura, Tatsuo, Welch, Stephen A., Lewsley, Liz Anne, Paoletti, Xavier, Cook, Adrian D.

المساهمون: Centre pour l'innovation en cancérologie de Lyon (CICLY), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre Léon Bérard Lyon, Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut Curie Paris, Groupe d'Investigateurs National des Etudes des Cancers Ovariens et du sein, Gynaecologic Cancer Intergroup, University Claude Bernard, Hospices Civils de Lyon, HCL

المصدر: ISSN: 0959-8049 ; European Journal of Cancer ; https://hal.science/hal-04229567Test ; European Journal of Cancer, 2023, 191, ⟨10.1016/j.ejca.2023.112966⟩.

مصطلحات موضوعية: CA-125, KELIM, Ovarian cancer, Primary chemosensitivity, Prognostic biomarker, Surrogate end-point, [SDV.CAN]Life Sciences [q-bio]/Cancer

الوصف: International audience ; Background: In patients with advanced ovarian cancer, the modelled CA-125 ELIMination rate constant K (KELIM) is an early indicator of the tumour intrinsic chemosensitivity. We assessed the prognostic and surrogate values of KELIM with respect to those of surgery outcome (based on post-operative residual lesions) in the Gynaecologic Cancer Intergroup (GCIG) individual patient data meta-analysis MAOV (Meta-Analysis in OVarian cancer) built before the emergence of poly(ADP-ribose) polymerase (PARP) inhibitors. Methods: The dataset was split into learning and validation cohorts (ratio 1:2). The individual modelled KELIM values were estimated, standardised by the median value, then scored as unfavourable (<1.0) or favourable (≥1.0). Overall survival (OS) and progression-free survival (PFS) analyses were performed with a two-step meta-analytic approach and surrogacy through a two-level meta-analytic model. Results: KELIM was assessed in 5884 patients from eight first-line trials (learning, 1962; validation, 3922). A favourable KELIM score was significantly associated with longer OS (validation set, median, 78.8 versus 28.4 months, hazard-ratios [HR] 0.46, 95% confidence interval [CI], 0.41–0.50, C-index 0.68), and longer PFS (validation set, median 30.5 versus 9.8 months, HR 0.49, 95% CI, 0.45–0.54, C-index 0.68), as were International Federation of Gynaecology and Obstetrics (FIGO) stage and debulking surgery outcome. Three prognostic groups were identified based on the surgery outcome and KELIM score, with large differences in OS (105.1, ∼45.0, and 22.1 months) and PFS (58.1, ∼15.0, and 8.0 months). Surrogacy for OS and for PFS was not established. Conclusion: KELIM is an independent prognostic biomarker for survival, complementary to surgery outcome, representing a new determinant of first-line treatment success.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37542936; hal-04229567; https://hal.science/hal-04229567Test; https://hal.science/hal-04229567/documentTest; https://hal.science/hal-04229567/file/1-s2.0-S0959804923003180-main.pdfTest; PUBMED: 37542936

الإتاحة: https://doi.org/10.1016/j.ejca.2023.112966Test
https://hal.science/hal-04229567Test
https://hal.science/hal-04229567/documentTest
https://hal.science/hal-04229567/file/1-s2.0-S0959804923003180-main.pdfTest

المؤلفون: Corbaux, Pauline, You, Benoit, Glasspool, Rosalind M., Yanaihara, Nozomu, Tinker, Anna V., Lindemann, Kristina, Ray-Coquard, Isabelle Laure, Mirza, Mansoor Raza, Subtil, Fabien, Colomban, Olivier, Péron, Julien, Karamouza, Eleni, Mcneish, Iain A., Kelly, Caroline A., Kagimura, Tatsuo, Welch, Stephen A., Lewsley, Liz Anne, Paoletti, Xavier, Cook, Adrian D.

المساهمون: Centre pour l'innovation en cancérologie de Lyon (CICLY), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon, Centre Léon Bérard Lyon, Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Institut Curie Paris, Groupe d'Investigateurs National des Etudes des Cancers Ovariens et du sein, Gynaecologic Cancer Intergroup, University Claude Bernard, Hospices Civils de Lyon, HCL

المصدر: ISSN: 0959-8049 ; European Journal of Cancer ; https://hal.science/hal-04229567Test ; European Journal of Cancer, 2023, 191, ⟨10.1016/j.ejca.2023.112966⟩.

مصطلحات موضوعية: CA-125, KELIM, Ovarian cancer, Primary chemosensitivity, Prognostic biomarker, Surrogate end-point, [SDV.CAN]Life Sciences [q-bio]/Cancer

الوصف: International audience ; Background: In patients with advanced ovarian cancer, the modelled CA-125 ELIMination rate constant K (KELIM) is an early indicator of the tumour intrinsic chemosensitivity. We assessed the prognostic and surrogate values of KELIM with respect to those of surgery outcome (based on post-operative residual lesions) in the Gynaecologic Cancer Intergroup (GCIG) individual patient data meta-analysis MAOV (Meta-Analysis in OVarian cancer) built before the emergence of poly(ADP-ribose) polymerase (PARP) inhibitors. Methods: The dataset was split into learning and validation cohorts (ratio 1:2). The individual modelled KELIM values were estimated, standardised by the median value, then scored as unfavourable (<1.0) or favourable (≥1.0). Overall survival (OS) and progression-free survival (PFS) analyses were performed with a two-step meta-analytic approach and surrogacy through a two-level meta-analytic model. Results: KELIM was assessed in 5884 patients from eight first-line trials (learning, 1962; validation, 3922). A favourable KELIM score was significantly associated with longer OS (validation set, median, 78.8 versus 28.4 months, hazard-ratios [HR] 0.46, 95% confidence interval [CI], 0.41–0.50, C-index 0.68), and longer PFS (validation set, median 30.5 versus 9.8 months, HR 0.49, 95% CI, 0.45–0.54, C-index 0.68), as were International Federation of Gynaecology and Obstetrics (FIGO) stage and debulking surgery outcome. Three prognostic groups were identified based on the surgery outcome and KELIM score, with large differences in OS (105.1, ∼45.0, and 22.1 months) and PFS (58.1, ∼15.0, and 8.0 months). Surrogacy for OS and for PFS was not established. Conclusion: KELIM is an independent prognostic biomarker for survival, complementary to surgery outcome, representing a new determinant of first-line treatment success.

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/37542936; hal-04229567; https://hal.science/hal-04229567Test; https://hal.science/hal-04229567/documentTest; https://hal.science/hal-04229567/file/1-s2.0-S0959804923003180-main.pdfTest; PUBMED: 37542936

الإتاحة: https://doi.org/10.1016/j.ejca.2023.112966Test
https://hal.science/hal-04229567Test
https://hal.science/hal-04229567/documentTest
https://hal.science/hal-04229567/file/1-s2.0-S0959804923003180-main.pdfTest